Skip to main content

CGT Catapult: New guidance on the development and marketing of ATMPs in the UK and EU in the post-BREXIT landscape

The Cell and Gene Therapy Catapult (CGT Catapult) has outlined the latest guidance on the development and marketing of ATMPs in the UK. The guidance covers legislative changes as a result of the United Kingdom leaving the European Union, including topics such as clinical trials, ATMP classifications, UK Marketing Authorisations, UK Paediatric Investigation Plans, orphan drug designation, MHRA submission platform and advice meetings.

The guide is available as a PDF to download or view online. 

 

CGT Catapult new guidance

New guidance on the development and marketing of ATMPs in the UK and EU in the post-BREXIT landscape

  More CGT Catapult resources can be found here.

Did you find the content on this page useful? If not, you can leave us a message so we can improve Send us your thoughts